Keywords
inmunoproteosoma
enfermedades autoinmunes
autoinflamatorias
How to Cite
Abstract
The proteasome and its immunoproteasome variant play essential roles in intracellular protein degradation, cell cycle regulation, and antigen presentation. Dysregulation of these complexes has been linked to the pathogenesis of various autoimmune and autoinflammatory diseases. This systematic review analyzed the available evidence regarding the pathogenic role of the proteasome in conditions such as rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, Sjögren’s syndrome, multiple sclerosis, autoimmune thyroiditis, inflammatory bowel disease, and PRAAS syndromes. The immunoproteasome is highlighted as a key regulator of T-cell differentiation and pro-inflammatory cytokine production, while genetic mutations in proteasome subunits have been associated with autoinflammatory syndromes. Finally, the therapeutic potential of proteasome inhibitors such as bortezomib and ONX 0914 is discussed, showing promising preclinical results but requiring further studies to establish their safety and clinical applicability.
References
(1) Śledź P, Baumeister W. Structure-driven developments of 26S proteasome inhibitors. Annu Rev Pharmacol Toxicol [Internet]. 2016;56(1):191–209. Disponible en: http://dx.doi.org/10.1146/annurev-pharmtox-010814-124727.
(2) Tanaka K. The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci [Internet]. 2009;85(1):12–36. Disponible en: http://dx.doi.org/10.2183/pjab.85.12.
(3) Goetzke CC, Ebstein F, Kallinich T. Role of proteasomes in inflammation. J Clin Med [Internet]. 2021;10(8):1783. Disponible en: http://dx.doi.org/10.3390/jcm10081783.
(4) Abi Habib J, Lesenfants J, Vigneron N, Van den Eynde BJ. Functional differences between proteasome subtypes. Cells [Internet]. 2022;11(3):421. Disponible en: http://dx.doi.org/10.3390/cells11030421.
(5) Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S74-9.
(6) van den Eshof BL, Medfai L, Nolfi E, Wawrzyniuk M, Sijts AJAM. The function of immunoproteasomes-an immunologists’ perspective. Cells [Internet]. 2021;10(12):3360. Disponible en: http://dx.doi.org/10.3390/cells10123360.
(7) Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. Immunity [Internet]. 2022;55(12):2255–70. Disponible en: http://dx.doi.org/10.1016/j.immuni.2022.11.009.
(8) Ruscitti P, Currado D, Rivellese F, Vomero M, Navarini L, Cipriani P, et al. Diminished expression of the ubiquitin-proteasome system in early treatment-naïve patients with rheumatoid arthritis and concomitant type 2 diabetes may be linked to IL-1 pathway hyper-activity; results from PEAC cohort. Arthritis Res Ther [Internet]. 2024;26(1):171. Disponible en: http://dx.doi.org/10.1186/s13075-024-03392-9.
(9) Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum [Internet]. 2012;64(2):493–503. Disponible en: http://dx.doi.org/10.1002/art.33333.
(10) Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol [Internet]. 2014;192(12):5459–68. Disponible en: http://dx.doi.org/10.4049/jimmunol.1002795.
(11) Witte T. Sjögren’s syndrome. Z Rheumatol [Internet]. 2019;78(6):511–7. Disponible en: http://dx.doi.org/10.1007/s00393-019-0625-8.
(12) Wang H, Tan Y, Liu Q, Yang S, Cui L. Ubiquitin-proteasome system: a potential participant and therapeutic target in antiphospholipid syndrome. Front Immunol [Internet]. 2025;16:1523799. Disponible en: http://dx.doi.org/10.3389/fimmu.2025.1523799.
(13) Aparicio-Vera LA, García-Herrera IP. GEN POMP: acerca de su participación en los mecanismos de autoinmunidad e inflamación. Rev parag reumatol [Internet]. 2024;10(1):30–6. Disponible en: http://dx.doi.org/10.18004/rpr/2024.10.01.30.
(14) Mendonça LO, Frémond M-L. Interferonopathies: From concept to clinical practice. Best Pract Res Clin Rheumatol [Internet]. 2024;38(3):101975. Disponible en: http://dx.doi.org/10.1016/j.berh.2024.101975.
(15) Kisselev AF. Site-specific proteasome inhibitors. Biomolecules [Internet]. 2021;12(1):54. Disponible en: http://dx.doi.org/10.3390/biom12010054.
(16) Weyburne ES, Wilkins OM, Sha Z, Williams DA, Pletnev AA, de Bruin G, et al. Inhibition of the proteasome β2 site sensitizes triple-negative breast cancer cells to β5 inhibitors and suppresses Nrf1 activation. Cell Chem Biol [Internet]. 2017;24(2):218–30. Disponible en: http://dx.doi.org/10.1016/j.chembiol.2016.12.016.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Jennifer González Vélez, Mariel León Bonifacio, Iris Paola García Herrera, Luis Alberto Aparicio Vera